Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer
Peter RufDepartment of Antibody Development, TRION Research GmbH, Martinsried, Germany;Olivier GiresClinical Cooperation Group Molecular Oncology, GSF-Research Centre for Health, and Environment and Department of Otorhinolaryngology, Ludwig-Maximilians-University, Munich, Germany;Michael JägerKarin FellingerClinical Cooperation Group Molecular Oncology, GSF-Research Centre for Health, and Environment and Department of Otorhinolaryngology, Ludwig-Maximilians-University, Munich, Germany;Judith AtzDepartment of Preclinical Research and Development, Fresenius Biotech GmbH, Gra felf ing, Germany;Horst LindhoferCEO, TRION Pharma GmbH, Munich, Germany
2007en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 2Использованных источников: 0